Cargando…
Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
Multiple myeloma (MM) is a currently incurable hematologic cancer. This disease is characterized by immunological alterations of myeloid cells and lymphocytes. The first-line therapy involves the use of classic chemotherapy; however, many patients have a relapsed form that could evolve into a refrac...
Autores principales: | De Luca, Fabiola, Allegra, Alessandro, Di Chio, Carla, Previti, Santo, Zappalà, Maria, Ettari, Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959320/ https://www.ncbi.nlm.nih.gov/pubmed/36834545 http://dx.doi.org/10.3390/ijms24043136 |
Ejemplares similares
-
Dipeptide Nitrile CD34 with Curcumin: A New Improved Combination Strategy to Synergistically Inhibit Rhodesain of Trypanosoma brucei rhodesiense
por: Di Chio, Carla, et al.
Publicado: (2023) -
Drug Combination Studies of the Dipeptide Nitrile CD24 with Curcumin: A New Strategy to Synergistically Inhibit Rhodesain of Trypanosoma brucei rhodesiense
por: Di Chio, Carla, et al.
Publicado: (2022) -
Development of Reduced Peptide Bond Pseudopeptide Michael Acceptors for the Treatment of Human African Trypanosomiasis
por: Previti, Santo, et al.
Publicado: (2022) -
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2021) -
Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells
por: Ettari, Roberta, et al.
Publicado: (2019)